إعلان
إعلان

ZNTL

ZNTL logo

Zentalis Pharmaceuticals, Inc. Common Stock

2.42
USD
برعاية
+0.64
+36.24%
٠٧ يناير, ١٥:٥٨ UTC -5
مغلق
exchange

بعد الإغلاق

2.42

0.00
-0.21%

تقارير أرباح ZNTL

النسبة الإيجابية المفاجئة

ZNTL تفوق 12 من 23 آخر التقديرات.

52%

التقرير التالي

بيانات التقرير القادم
٢٤ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.43
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/
+16.22%
التغير الضمني من Q4 24 (Revenue/ EPS)
-100.00%
/
-30.65%

Zentalis Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On ١٠ نوفمبر ٢٠٢٥, ZNTL reported earnings of -0.37 USD per share (EPS) for Q3 25, beating the estimate of -0.53 USD, resulting in a 31.28% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +6.06% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 11 المحللين forecast an EPS of -0.43 USD, with revenue projected to reach -- USD, implying an زيادة of 16.22% EPS, and زيادة of 0.00% in Revenue from the last quarter.
الأسئلة الشائعة
For Q3 2025, Zentalis Pharmaceuticals, Inc. Common Stock reported EPS of -$0.37, beating estimates by 31.28%, and revenue of $0.00, 0% as expectations.
The stock price moved up 6.06%, changed from $1.32 before the earnings release to $1.40 the day after.
The next earning report is scheduled for ٢٤ مارس ٢٠٢٦.
Based on 11 المحللين, Zentalis Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.43 and revenue of -- for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان